Monthly summary – May 2024

Artificial Intelligence and earnings trumped rates and politics. Even though worries over possible rate cut delays by central banks, and the increasingly uncertain political and geopolitical landscape weighed down on investor sentiment, equity markets overall rose in May, led yet again by technology stocks.

Interest rate setback

The stickier-than-expected inflation made for yet another setback to expectations regarding when central banks might lower their interest rates. In the US, consensus was lowered to one or possibly two cuts taking place during the fall of 2024; a far cry from the hopes raised at the beginning of the year. One Federal Reserve committee member even voiced the possibility of a hike. Whereas some central banks in Europe (Switzerland and Sweden) made cuts, the European Central Bank was generally expected to follow suit in June, but to then do nothing until inflation was down to its two percent target.

 Earnings season – better than expected

With the earnings season more or less over, the AI behemoth Nvidia released its Q1 earnings in late May. Once again, results surpassed estimates and the chipmaker’s shares rallied. After a more than 3,000 percent gain in the last five years, Nvidia is now the third-largest US corporation in terms of market cap. Otherwise, to sum up the first quarterly reports, outcomes were, on balance, better than expected implying that the world economy was humming along, even though regional differences were significant.

 Presidential election picked up momentum

The run-up to the US presidential election in November gained some momentum last month, not least because Donald Trump was found guilty in a New York court on charges related to the payout of ”hush-money”. Democrats welcomed the conviction, while Republicans saw the trial as being politically motivated and generally continued to back Mr. Trump as the party’s candidate.

 General election called in the UK

In the UK, prime minister Rishi Sunak surprisingly called a general election on July 4th, half a year before what had been expected. With the Conservative party trailing Labor by tens of percentage points, investors began bracing themselves for a new, more leftist government. Having been in the doldrums ever since the Brexit referendum eight years ago, UK equities traded at a discount to many other developed markets.

 No improvement in Ukraine or Gaza

No improvement was seen in the two active war zones, Ukraine and Gaza. Following the recent Russian onslaught around Kharkiv, Ukraine responded with drone attacks on targets inside Russia, especially oil and gas installations. Despite increased international pressure on Israel, the IDF continued its operations in Rafah, aimed at destroying Hamas. The accidental bombing of a refugee camp led to massive protests around the world and several countries, including Norway, Spain and Ireland, decided to recognize Palestine.

Technology sector in the driver’s seat

In US dollar terms, the world index advanced in May. However, continued foreign exchange fluctuations meant that returns were again dependent on investors’ base currency. The increase in the index was almost entirely attributable to the technology sector (and to a much lesser degree to utilities), while most other sectors fared significantly less well, with energy and industrials trailing the most. Given its dominance in information technology, the US markets outperformed the rest of the world, with Japan and Hong Kong posting the worst returns. 

OUTLOOK

The timing of the first interest rate cut in the US has been postponed and many economists and strategists now see November as the earliest possible time for the cut to happen. A strong labor market combined with the lingering high inflation means that the Fed prefers to keep the interest rate at its current level for a while longer. There is considerable discussion about whether the present interest rate level is dampening economic activity sufficiently enough to help bring inflation down towards the two percent goal. It is impossible to know for sure, one reason being that the increase in interest rates already implemented takes time to affect the cost of dwelling. Doubters exist but they have no more data than anyone else to prove their thesis.

We see tendencies towards a slightly weaker labor market as well as lower inflation, which is why our assessment is that September, as the month for the first interest rate cut, is actually a reasonable guess. This means that it is quite possible to have a strong stock market during the summer, which is usually the case during the year of an American presidential election where the incumbent president is running for re-election. Although this is not based on a statistically valid sample, it is seen by many as a pattern validated by history.

Continued strong outlooks for the sector

Fundamentally, it is well founded for this particular year with good reports for the first quarter and continued high liquidity in the financial markets. For the healthcare sector, it is becoming particularly interesting. The second half of the year has good opportunities to be strong since last year’s profit development was marked by some cost pressure and was combined with relatively low healthcare production as a result of labor shortages in healthcare. It remains to be seen if the stock market will discount this already this summer or if it will wait until after the election. We’ll simply have to wait and see.

Andra nyheter från oss

All

Direkt

Finwire

Uncategorized

Rhenman & Partners

Monthly comment (Apr 25): Healthcare sector impacted by political uncertainty

Monthly summary – March 2025: a volatile month, again impacted by the macro-economic and political backdrop

Rhenman Healthcare Equity L/S minskade 13,61 procent i mars – volatilt för hälsovårdssektorn

Monthly summary – February 2025: Sentiment turned sour in February

Rhenman Healthcare Equity L/S sjönk 4,52 procent i februari – politisk osäkerhet pressade marknaden

Rhenman & Partners strengthens its Operations Team

Rhenman & Partners förstärker sitt Operationsteam

Monthly comment – January 2025: All sectors except technology closing in positive territory

Rhenman Healthcare Equity L/S ökade 8,41 procent i januari – stark rotation mot hälsovård

Monthly comment – December 2024

Rhenman Healthcare Equity L/S minskade 10,48 procent i december – tungt avslut på 2024

Monthly summary – November 2024: Once the election results were in, focus shifted torwards likely economic implications

Rhenman Healthcare Equity L/S ökade 1,67 procent i november – volatilt efter valet i USA

How is the healthcare sector affected by the US election results?

Hur påverkas en av världens mest reglerade sektorer av valutgången i USA?

Rhenman Healthcare Equity L/S minskade 2,00 procent i oktober – fokus på rapportperiod och USA-val

October 2024 summary – Initital focus on the earnings season switched to focus on election outcomes

Rhenman Healthcare Equity L/S föll 3,53 procent i september – positiv långsiktig utsikt trots volatil marknad

Monthly summary – September 2024

Rhenman & Partners strengthens its Investor Relations team further

Rhenman & Partners förstärker sitt Investor Relations-team ytterligare

Monthly summary – August 2024

Rhenman Healthcare Equity L/S ökade 3,35 procent i augusti – optimistisk syn på andra halvåret

Rhenman & Partners förstärker investeringsteamet – ytterligare en portföljförvaltare inom biopharma

Rhenman & Partners strengthens investment team – hires additional biopharma PM

Rhenman Healthcare Equity L/S ökade 5,26 procent i juli – tydlig sektorrotation

Monthly update – July 2024

Rhenman Healthcare Equity L/S ökade 1,42 procent i juni – stark månad för aktiemarknaden

Monthly summary – June 2024

Rhenman & Partners celebrates 15 years

Rhenman Healthcare Equity L/S föll 1,29 procent i maj – ser positivt på andra halvåret

Rhenman Healthcare Equity L/S minskade 2,57 procent i april – svag utveckling för de flesta delsektorer

Monthly summary – April

Rhenman Healthcare Equity L/S ökade 5,86 procent i mars – starka bidrag från medicinteknik

Monthly summary – March 2024

Rhenman & Partners strengthens its investor relations team

Rhenman & Partners förstärker Investor Relations

Rhenman Healthcare Equity L/S ökade 4,45 procent i februari – stark månad för bioteknik

Monthly summary – February 2024

Rhenman Healthcare Equity ökade 6,17 procent i januari – Shockwave och Eli Lilly bidrog positivt

Monthly summary – January 2024

Monthly summary – December 2023

Rhenman Healthcare Equity L/S ökade 5,43 procent i december – Cytokinetics bidrog positivt till utvecklingen

Monthly summary – November 2023

Monthly update – November 2023

Rhenman Healthcare Equity ökade 3,58 procent i november – Immunogen bidrog positivt

Monthly summary – October

Rhenman Healthcare Equity minskade 3,03 procent i oktober – två uppköp under månaden

The complex reality of investing in Biopharma

Rhenman Healthcare Equity minskade 6,07 procent i september – Immunovant steg kraftigt efter goda resultat

Monthly summary – September

Rhenman Healthcare Equity ökade 2,91 procent i augusti – Eli Lilly och Novo Nordisk i blickfånget

MONTHLY SUMMARY – AUGUST 2023

Rhenman Healthcare Equity minskade 4,01 procent i juli – Apellis Pharmaceuticals tyngde utvecklingen

Rhenman Healthcare Equity L/S ökade 2,65 procent i juni – ökar allokeringen mot tryggare bolag

Monthly summary – June 2023

Susanna Urdmark lämnar Rhenman & Partners

Susanna Urdmark to leave Rhenman & Partners

Susanna Urdmark lämnar Rhenman & Partners

Rhenman Healthcare Equity ökade 3,24 procent i maj – Immunogen bidrog positivt till utvecklingen

Dan Hoflund ny styrelseledamot för Rhenman & Partners Asset Management

Rhenman Healthcare Equity L/S ökade 3,83 procent i april – Tenet Health utvecklades starkt

Monthly summary – April 2023

Rhenman Healthcare Equity L/S minskade 1,02 procent i mars – Novo Nordisk aktiekurs fortsätter stiga

Monthly summary – March 2023

Lars Wedenborn ny styrelseledamot för Rhenman & Partners Asset Management

Lars Wedenborn – ny styrelseledamot Rhenman & Partners Asset Management

Rhenman Healthcare Equity L/S minskade 4,42 procent i februari – rekyl på aktiemarknaderna under februari

Monthly summary – February 2023

Rhenman Healthcare Equity ökade 3,75 procent i januari – Revance Therapeutics och Tenet Healthcare bidrog positivt (uppdatering)

Rhenman Healthcare Equity ökade 3,75 procent i januari – Revance Therapeutics och Tenet Healthcare bidrog positivt

Monthly summary – January 2023

Rhenman Healthcare Equity minskade 4,76 procent i december – Horizon Therapeutics främsta bidragsgivare

Monthly summary – December 2022

Rhenman & Partners strengthens its investment team with a biopharma analyst

Rhenman & Partners förstärker sitt investeringsteam med biopharmananlytiker

Rhenman Healthcare Equity L/S ökade 2,51 procent i november – Abiomed och Horizon Health bidrog positivt

Summary – November 2022

Rhenman Healthcare Equity L/S: +5,7% i oktober, flera faktorer pekar på hyfsad vinter men makrorisker ska ej underskattas – förvaltare

Summary – October 2022

Rhenman Healthcare Equity L/S ökade 5,68 procent i oktober – lyfter fram potentiell presidentcykeleffekt

Rhenman Healthcare Equity L/S: -1,5% i september, investmentbanker sänkte Jazz Pharmaceuticals och Vitrolife (R)

Rhenman Healthcare Equity L/S minskade 1,5 procent i september – Revance Therapeutics och Regeneron Pharmaceuticals främsta bidragsgivare

Teresa Isele ny vd för Rhenman & Partners Asset Management

Teresa Isele ny VD för Rhenman & Partners Asset Management AB

Teresa Isele to be the new CEO of Rhenman & Partners Asset Management AB

Rhenman Healthcare Equity L/S: +1,7% i augusti, förvaltare positiva till amerikansk läkemedelsreform

Rhenman Healthcare Equity L/S ökade 1,70 procent i augusti – biotekniksektorn gynnade utvecklingen

Rhenman Healthcare Equity L/S RC1 SEK: +5,4% i juli, ser på uppgångarna med försiktighet

Rhenman Healthcare Equity L/S ökade 5,39 procent i juli – fortsatt försiktig inställning

Rhenman Healthcare Equity L/S: +4,5% i juni, ser inte läge att öka aktieexponering trots viss ljusning.

Rhenman Healthcare Equity L/S ökade 4,50 procent i juni – stark återhämtning från små- och medelstora bioteknikbolag

Rhenman Healthcare Equity L/S minskade 3,19 procent i maj – stora läkemedelsbolag bidrog positivt

RHENMAN HEALTHCARE EQUITY L/S: -3,2% I MAJ, BUD PÅ BIOHAVEN

Rhenman & Partners fortsätter att expandera – sök rollen som biopharma-analytiker

Rhenman & Partners winner of Refinitiv Lipper Fund Awards Nordics

Rhenman & Partners vinnare av internationellt fondpris

Lediga tjänster inom Investor Relations

Rhenman Healthcare Equity L/S: -4,9% i april, tyngdpunkt på stora bolag för tillfället

Rhenman Healthcare Equity L/S minskade 4,93 procent i april – läkemedelsbolag minst påverkade av ökad global osäkerhet

EN